3 U.S. E&P Stocks That Look Well Placed for the Road Ahead
Following a careful analysis of the Zacks Oil and Gas - Exploration and Production - United States industry, we advise tracking shares of WTI, APA and FANG.
APA - APA Corporation
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$45.23
DETAILS
HIGH:
$62.00
LOW:
$36.00
MEDIAN:
$44.00
CONSENSUS:
$45.23
UPSIDE:
1.12%
Stock News
APA (APA) Up 20.9% Since Last Earnings Report: Can It Continue?
APA (APA) reported earnings 30 days ago. What's next for the stock?
Eni Builds Uruguay Offshore Presence Through New Exploration Deals
E deepens its Uruguay offshore push with exploration deals for OFF-5 and OFF-6 blocks, while backing a planned 2027 well in OFF-6.
Here's Why APA (APA) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why APA (APA) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why APA (APA) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel the proposed licensing of APA-01 to Restora Neurosciences, and will evaluate in-house and co-development pathways Canaccord Genuity LLC has been engaged as exclusive financial advisor and placement agent TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates. 1. U.S. Patent Granted for Novel Enantioselective Manufacturing Processes PharmAla has been granted United States Patent No.
NFWF Announces $1.2 Million for Pecos River Watershed Restoration and Native Species Recovery
Four grants generate $2.6 million in conservation impact to enhance grassland habitat, restore aquatic habitats and conserve desert fish species found nowhere else in the world Four grants generate $2.6 million in conservation impact to enhance grassland habitat, restore aquatic habitats and conserve desert fish species found nowhere else in the world
ARRAY Technologies to Detail Balance-of-System Strategy and APA Long-Term Growth Opportunities at the APA Investor Technology Showcase Today
ALBUQUERQUE, N.M., Aug. 20, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology and fixed-tilt products, foundation solutions, software systems and services, will host its previously announced APA Investor Technology Showcase today, Thursday, August 20, 2026, beginning at 9:00 a.m.
APA Group Stapled Securities (APAJF) Q4 2026 Earnings Call Transcript
APA Group Stapled Securities (APAJF) Q4 2026 Earnings Call Transcript
HOTCHKIS & WILEY Trims APA Corp (APA) Stake -- Shares Trade 62% Above GF Value
On June 30, 2026, Hotchkis and Wiley filed a 13DG report with the Securities and Exchange Commission, disclosing a reduction of 319,811 shares in APA Corp (NASDAQ
APA Targets $700M Cost Cuts, 5% Oil Growth as Suriname Project Nears 2028 Start
APA NASDAQ: APA outlined a strategy centered on cash-generating operations in the Permian Basin and Egypt, cost reductions and a global exploration portfolio that management believes can support future production growth.
APA Corporation: Fundamentals Keep Improving As The Re-Rating Case Gets Stronger
APA Corporation remains a Strong Buy, driven by robust free cash flow, upsized cost savings, and upside from the Suriname project. APA beat top- and bottom-line estimates again, raised 2026 Permian oil guidance, and maintained capital discipline, with net leverage at a solid ~0.6x. Debt reduction and cost savings are on track, with $752 million in bond repayments in H1 2026 and $675 million in annualized cost/interest benefits.
APA and Woodside Energy Have Fuel in the Tank to Go Higher
APA has jumped nearly 100% over the last year, while Woodside Energy Group ADR is up by 32% year to date.
Should Investors Buy APA or Wait as Efficiency Meets Execution Risk?
APA's lower costs, stronger Permian efficiency and discounted valuation support the case, but commodity sensitivity and long project timelines temper upside.
APA Corporation: Five Years Of Portfolio Discipline, One Deepwater Bet
APA Corporation has prioritized strict deleveraging, portfolio consolidation, and disciplined capital returns over unbridled production growth since its 2021 reorganization. Recent milestones include the $4.5B Callon Petroleum acquisition, a structural cost-reduction target raised to $500M, and $230M worth of GranMorgu offshore development funding. Technical analysis reveals a confluence of nominal and commodity-ratio targets pointing to a near-term price level of ~$51.95 (an implied ~30% upside), with macro-fractal extensions reaching significantly higher.
APA Corp Q2 Earnings Beat Estimates on Higher Oil Prices
APA's Q2 earnings beat estimates as higher oil prices and lower expenses offset weaker revenues and natural gas prices.
Assenagon Asset Management S.A. Takes Position in APA Corporation $APA
Assenagon Asset Management S.A. purchased a new stake in APA Corporation (NASDAQ: APA) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 187,237 shares of the company's stock, valued at approximately $6,098,000. Assenagon Asset Management S.A. owned about 0.05% of APA at
APA Corporation $APA Shares Sold by Bank of America Corp DE
Bank of America Corp DE lessened its holdings in shares of APA Corporation (NASDAQ: APA) by 39.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,497,464 shares of the company's stock after selling 962,062 shares during the period.
APA (NASDAQ:APA) Trading Up 7.7% on Analyst Upgrade
APA Corporation (NASDAQ: APA - Get Free Report)'s stock price was up 7.7% on Monday after Truist Financial raised their price target on the stock from $38.00 to $39.00. Truist Financial currently has a hold rating on the stock. APA traded as high as $40.51 and last traded at $40.5320. Approximately 2,151,594 shares were traded during
Price Targets
APA Corp. initiated with a Buy at Stifel
$62.00
(was $44.84)
Stifel Nicolaus
APA Corp. price target raised to $43 from $31 at Goldman Sachs
$43.00
(was $42.77)
Goldman Sachs
APA Corp. assumed with an Equal Weight at Wells Fargo
$50.00
(was $44.30)
Noah Hungness
·
Wells Fargo
APA Corp. (APA) PT Raised to $54 at Raymond James
$54.00
(was $44.30)
John Freeman
·
Raymond James
Argus Upgrades APA Corp. (APA) to Buy
$48.00
(was $42.37)
Bill Selesky
·
Argus Research
APA Corp. price target raised to $49 from $39 at Wells Fargo
$49.00
(was $39.97)
Wells Fargo
APA Corp. (APA) PT Raised to $46 at Benchmark as Net Debt Declines
$46.00
(was $40.08)
KeyBanc
APA Corp. price target raised to $47 from $45 at Susquehanna
$47.00
(was $41.02)
Susquehanna
APA Corp. posts 'mixed' Q2 results, says Roth Capital
$39.00
(was $36.03)
Leo Mariani
·
Roth Capital
APA Corp. price target lowered to $45 from $47 at Susquehanna
$45.00
(was $35.26)
Susquehanna
APA Corp. price target lowered to $41 from $45 at UBS
$41.00
(was $33.96)
UBS
APA Corp. price target lowered to $50 from $57 at Raymond James
$50.00
(was $34.47)
Raymond James
APA Corp. price target lowered to $38 from $39 at Truist
$38.00
(was $33.19)
Gabe Daoud
·
Truist Financial
APA Corp. upgraded to Buy from Neutral at Roth Capital
$38.00
(was $33.03)
Leo Mariani
·
Roth Capital
APA Corp. price target raised to $36 from $32 at Mizuho
$36.00
(was $37.50)
Mizuho Securities
APA Corp. price target raised to $57 from $45 at Raymond James
$57.00
(was $38.52)
Raymond James
APA Corp. price target raised to $44 from $43 at Morgan Stanley
$44.00
(was $38.86)
Morgan Stanley
APA Corp. price target raised to $40 from $37 at Bernstein
$40.00
(was $35.56)
Bernstein
APA Corp. price target raised to $39 from $38 at Truist
$39.00
(was $36.42)
Gabe Daoud
·
Truist Financial
APA Corp. price target raised to $45 from $44 at UBS
$45.00
(was $34.03)
UBS